Biognosys Announces GLP Certification of Its Proteomics Facility by the Swiss Health Authorities
Biognosys, a leader in next-generation proteomics solutions for drug discovery and development, announced today that it has obtained Good Laboratory Practice (GLP) certification from Swiss health authorities for preclinical studies. With this certification, Biognosys has become the first global proteomics service provider to be GLP certified, alongside being fully compliant with Good Clinical Practice (GCP).
This regulatory milestone showcases Biognosys’ rigorous adherence to international research standards for preclinical and clinical studies. This achievement resulted from a partnership with Roche and the setup of an extensive quality management system for the purpose of using discovery proteomics in clinical trials, an effort that spanned several years.
Nadine Frankenberg, PhD, Head of Quality Assurance at Biognosys, commented: “The GLP certification by the Swiss health authorities is a strong recognition of our highly qualified personnel and the rigorous quality standards across all aspects of our services.”
Karel Novy, PhD, Chief Operating Officer of Biognosys, stated: “Delivering the best possible data in terms of depth and quality has always been at the core of Biognosys’ proteomics approach. Our recent GLP certification formalizes this long-standing effort and provides our customers with the opportunity to expand the use of proteomics across the full spectrum of preclinical and clinical studies.”
The GLP certification is based on the Swiss Ordinance on Good Laboratory Practice and the Organisation for Economic Co-operation and Development (OECD) principles on GLP. The certificate has been granted following an inspection of the Biognosys test facilities by the Swiss GLP Monitoring Authorities.
For clinical studies requiring GCP compliance, the company conforms to the ICH guideline for good clinical practice and the EMA reflection paper for laboratories that perform the analysis or evaluation of clinical trial samples.
Biognosys operates one of the largest high-end mass spectrometry laboratories in the world for large-scale proteomics contract research, offering industry-leading throughput while maintaining unprecedented precision and depth. Thanks to its experienced lab personnel, high-quality sample processing and high-throughput instruments park, Biognosys delivers projects with a fast turnaround time as required for clinical trials and routinely performs large-scale studies with more than 1,000 samples for global pharma and biotech customers, academia, or consortia.
Biognosys’ discovery proteomics solutions deploy proprietary, patented Hyper Reaction Monitoring (HRM™) technology and optimized liquid chromatography - mass spectrometry (LC-MS) workflows to search the complete proteome and quantify thousands of the most relevant proteins and peptide-level datapoints. They can be applied to tissues or biofluids across all biological species to provide a deep understanding of key disease pathways. In addition, the clinical transferability of this technology allows quick transition from early-stage discovery to specific, targeted panels that can be applied in a regulated setting.
About Biognosys
Biognosys is a leader in next-generation proteomics, dedicated to transforming life science by inventing and developing cutting-edge proteomics technology and solutions and making them widely available for pharmaceutical and biotechnology researchers and proteomics experts. The Company offers a versatile portfolio of proprietary proteomics services, software, and kits that provide a multi-dimensional view of protein expression, function, and structure in all biological species and sample types. Biognosys’ unique, patented technologies utilize high-resolution mass spectrometry to quantify thousands of proteins across thousands of samples with industry-leading precision, depth, and throughput. Through advanced data analytics, Biognosys translates data into actionable insights for R&D and clinical research. More information at biognosys.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220113005041/en/
Contact information
Yves Serroen
Head of Marketing
Phone +41 (0) 79 571 09 21
yves.serroen@biognosys.com
About Business Wire
Business WireSubscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kalray Joins Arm Total Design, Extending Collaboration With Arm on Accelerated AI Processing24.4.2024 09:01:00 CEST | Press release
Kalray (Euronext Growth Paris: ALKAL), a leading provider of hardware and software solutions to accelerate data intensive workflows from Cloud to Edge, announced that it has extended its collaboration with Arm by joining Arm Total Design. Through a deeper connection to industry leaders who are leveraging Arm® Neoverse™ Compute Subsystems (CSS), Kalray can help more companies integrate its unique AI and data acceleration technology and help Arm ecosystem partners commercialize AI-based solutions in a fraction of the time and cost usually needed. Arm Total Design helps accelerate and simplify the delivery of custom silicon based on Arm Neoverse CSS and has grown to more than 20 partners, including the top three leading foundries, ASIC design houses, IP vendors, EDA tool providers, and firmware developers who are driving leading-edge innovation. Kalray is already working to integrate Arm Coherent Mesh Network (CMN) technology to help easily connect Kalray’s advanced AI and data processing
Suzano Ventures invests up to US$5 million into Bioform Technologies to further develop bio-based plastic alternatives24.4.2024 09:01:00 CEST | Press release
Suzano Ventures, the corporate venture capital arm of Suzano, the world’s largest market pulp producer, has made a strategic investment into the Canadian materials science startup, Bioform Technologies. The investment provides up to US$5 million towards the company’s seed round, enabling it to accelerate the development of its novel bio-based plastic alternatives. The products can be manufactured through modified industrial processes already used in the pulp and paper sector. Bioform’s proprietary technology rapidly produces wood pulp-reinforced hydrogels to create high-performance plastic alternatives, which can be made using Suzano’s wood pulp fibre as a key input. Bioform’s materials have the potential to be home compostable or recycled through existing paper recycling processes and do not require fossil-based inputs. The technology is highly versatile and has a number of applications where it could replace conventional single-use plastics, including paper recyclable thermoformable
SES’s O3b mPOWER System Starts Providing High-performance Connectivity Services24.4.2024 08:50:00 CEST | Press release
SES announced today that O3b mPOWER, its second-generation software-enabled satellite system, is now operational and can provide high-performance connectivity services around the globe. With the first six O3b mPOWER satellites operating at medium Earth orbit (MEO) or 8,000km away from the Earth and with extensive ground infrastructure built around the world, SES will be introducing services in the coming months to O3b mPOWER customers to deliver reliable connectivity services ranging from tens of Mbps to multiple gigabits per second. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240423122963/en/ SES’s O3b mPOWER System Starts Providing High-performance Connectivity Services (Photo: Business Wire) To date, SES has launched six out of 13 O3b mPOWER high-throughput and low-latency satellites, which together with strategically located satellite ground stations, enable SES to serve customers across multiple market segments aroun
Galderma Delivers a Strong Start to the Year With Record Net Sales of Over 1 Billion USD for the First Quarter and 12.4% Year-on-Year Growth24.4.2024 07:00:00 CEST | Press release
Galderma Group AG (SWX:GALD), the pure-play dermatology category leader, today announced its sales performance for the first quarter of 2024. Record net sales of 1.071 billion USD in the first quarter of 2024, surpassing for the first time the 1 billion USD mark for the first three months in a year Net sales growth for the first quarter of 2024 was 12.4% year-on-year on a constant currency basis1, primarily driven by volume Broad-based growth across all product categories, with constant currency year-on-year growth of 19.3% for Injectable Aesthetics, 8.4% for Dermatological Skincare, and 4.1% for Therapeutic Dermatology Growth across geographies, especially in International markets while U.S. growth accelerated year-on-year 2024 full year guidance confirmed: 7-10% net sales year-on-year growth at constant currency and Core EBITDA margin in line with 2023 at constant currency Continued execution of Galderma’s integrated dermatology strategy, progressing on its innovation pipeline, comme
FPT Cooperates with USAID to Promote Clean Energy Deployment, Reduce Greenhouse Gas Emissions, and Accelerate Net Zero Transition24.4.2024 06:35:00 CEST | Press release
FPT Corporation signed Letter of Cooperation with the United States Agency for International Development’s (USAID) Vietnam Low Emission Energy Program II (V-LEEP II), with the goal of supporting the corporation in achieving the Net Zero target by 2040, a decade earlier than Vietnam's commitment. FPT is Vietnam’s first technology firm to collaborate with V-LEEP II. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240423349833/en/ The signing ceremony was attended by FPT Corporation Senior Executive Vice President Nguyen The Phuong, FPT Software Senior Executive Vice President Nguyen Khai Hoan, and USAID/Vietnam Deputy Mission Director Bradley Bessire (Photo: Business Wire) In accordance with the agreements, V-LEEP II will provide technical assistance to FPT from April 2024 to April 2025 as the corporation formulates a plan to execute its net-zero commitments. This entails providing a comprehensive understanding of Net Zero stra
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom